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Abstract
Background: Overexpression of the bZip transcription factor, ATF3, in basal epithelial cells of transgenic mice under the
control of the bovine cytokeratin-5 (CK5) promoter has previously been shown to induce epidermal hyperplasia, hair follicle
anomalies and neoplastic lesions of the oral mucosa including squamous cell carcinomas. CK5 is known to be expressed in
myoepithelial cells of the mammary gland, suggesting the possibility that transgenic BK5.ATF3 mice may exhibit mammary gland
phenotypes.
Methods: Mammary glands from nulliparous mice in our BK5.ATF3 colony, both non-transgenic and transgenic, were examined
for anomalies by histopathology and immunohistochemistry. Nulliparous and biparous female mice were observed for possible
mammary tumor development, and suspicious masses were analyzed by histopathology and immunohistochemistry. Human
breast tumor samples, as well as normal breast tissue, were similarly analyzed for ATF3 expression.
Results: Transgenic BK5.ATF3 mice expressed nuclear ATF3 in the basal layer of the mammary ductal epithelium, and often
developed squamous metaplastic lesions in one or more mammary glands by 25 weeks of age. No progression to malignancy
was seen in nulliparous BK5.ATF3 or non-transgenic mice held for 16 months. However, biparous BK5.ATF3 mice developed
mammary carcinomas with squamous metaplasia between 6 months and one year of age, reaching an incidence of 67%.
Cytokeratin expression in the tumors was profoundly disturbed, including expression of CK5 and CK8 (characteristic of basal
and luminal cells, respectively) throughout the epithelial component of the tumors, CK6 (potentially a stem cell marker), CK10
(a marker of interfollicular epidermal differentiation), and mIRSa2 and mIRSa3.1 (markers of the inner root sheath of hair
follicles). Immunohistochemical studies indicated that a subset of human breast tumors exhibit high levels of nuclear ATF3
expression.
Conclusion: Overexpression of ATF3 in CK5-expressing cells of the murine mammary gland results in the development of
squamous metaplastic lesions in nulliparous females, and in mammary tumors in biparous mice, suggesting that ATF3 acts as a
mammary oncogene. A subset of human breast tumors expresses high levels of ATF3, suggesting that ATF3 may play an
oncogenic role in human breast tumorigenesis, and therefore may be useful as either a biomarker or therapeutic target.
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Background
Most human ductal breast carcinomas express cytokeratin
(CK) markers characteristic of the luminal epithelial cell
compartment, namely CK8 and CK18 [1]. In the past, this
led to an overall interest among cancer biologists in cell
compartments containing luminal progenitor cells as the
possible target populations for carcinogenesis leading to
invasive ductal carcinoma (IDC). This is reflected in the
extensive development of transgenic mouse models of
breast cancer based on promoters thought to be active in
such cells, namely the MMTV promoter and pregnancy/
lactation specific promoters [2]. However, recently several
large surveys have revealed that a significant fraction of
invasive ductal carcinomas, 25–30%, express CK5 and/or
CK14, cytokeratins that are characteristic of myoepithelial
cells [1,3], resulting in renewed interest in the myoepithe-
lial cell lineage as the target population for some cancers
[4]. The subset of breast cancers that are CK5/14-positive
is enriched for the so-called basal-like tumors, identified
on the basis of large scale gene expression patterns [5-9].
This subset is of particular interest because these tumors
tend to be negative for estrogen receptor alpha (ERα),
lymph node positive and have a generally poor
prognosis [7,8].
The exact location and properties of undifferentiated, pro-
genitor cells that give rise to luminal and myoepithelial
cells in the adult breast is not well defined [4,10,11], and
hence the hierarchical relationships between progenitor
populations that may be targets for cancer induction are
still speculative. One theory suggests that mammary stem
cells give rise to separate populations of undifferentiated
progenitor cells for the two major pathways, and that
these luminal or myoepithelial progenitor cells may rep-
resent the targets for carcinogenesis [12]. However, several
findings argue against this model.
First, the vast majority of the CK5/14-positive IDCs also
express CK8/18, and very few tumors (< 1%) express
solely myoepithelial markers [1]. Secondly, genetic stud-
ies of IDC indicate that most occurrences of loss of heter-
ozygosity include both luminal and myoepithelial cells
[13], implying that the original genetic event occurred in
a precursor population that had the capability to give rise
to both compartments. These findings suggest that either
the predominant target population for induction of IDC
is a progenitor population capable of differentiating along
both luminal and myoepithelial lineages [10,11,14,15],
or that tumor cells derived from a restricted progenitor
population are capable of transdifferentiating, at least in
terms of the expression of CK markers.
It has been suggested that progenitor cells capable of dif-
ferentiating along both pathways exist that already express
some of the genes characteristic of the basal, myoepithe-
lial compartment [10,15,16], notably CK5/14. Indeed,
several transgenic mouse models of mammary cancer
have been developed that support this idea. Glukhova
and colleagues used the CK5 promoter to overexpress a β-
catenin variant, ΔN59Cat, that cannot be phosphorylated
at a site necessary for normal turnover [17]. Hence, these
mice accumulate transcriptionally active β-catenin in
CK5-expressing cells, mimicking the effects of Wnt path-
way stimulation. The nulliparous CK5. ΔN59Cat mice
exhibit hyperplasia of the myoepithelial cell compart-
ment of the mammary gland. However, multiparous
transgenic animals exhibit a high incidence of mammary
tumors, including both CK5+CK10+ squamous cell carci-
nomas, and invasive carcinomas that express both CK5
and CK8. Another mouse model that supports this con-
cept used the CK14 promoter to drive Cre-dependent
recombination that resulted in the loss of two tumor sup-
pressor genes, TP53 and BRCA2 [18]. Two-thirds of the
double knockout females develop mammary tumors by
one year of age that exhibit both luminal and myoepithe-
lial differentiation. Thus, ample evidence exists that
genetic alterations affecting CK5/14-expressing cells, pre-
sumably a progenitor population, can give rise to IDC that
contain cells with characteristics of both the luminal and
myoepithelial lineages.
We have recently described a transgenic mouse model in
which the bovine CK5 promoter drives expression of the
human ATF3 gene [19]. ATF3 is a transcription factor in
the bZip family whose expression is induced during the
response to DNA damage and other forms of cellular
stress in a wide variety of tissues and cell types [20-22].
However, the physiological function of ATF3 is unknown,
and its downstream transcription targets have not been
extensively defined. These BK5.ATF3 mice exhibit several
epidermal phenotypes, including a gross hyperplasia of
the outer root sheath cells of the hair follicles, resulting in
abnormal hair growth, and a milder hyperplasia of the
interfollicular epidermis [19]. Additionally, aged trans-
genic mice (16 months) develop oral cavity neoplasias at
high frequency including both squamous cell carcinomas,
and a class of basal cell tumors with heterogeneous differ-
entiation. We now describe several mammary phenotypes
of heterozygous BK5.ATF3 mice, including the presence of
cystic, squamous metaplasias in nulliparous female ani-
mals and a high incidence (67%) of mammary carcino-
mas with squamous features in parous females by one
year of age.
Methods
BK5.ATF3 mice
As described previously [19], transgenic BK5.ATF3 mice
were obtained by embryo injection in FVB/N mice. The
construct for these experiments contained the human
ATF3 cDNA sequence [23] in an expression vector con-BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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taining the bovine keratin 5 promoter [24]. This promoter
is active in basal epithelial cells in several tissues, includ-
ing skin, thymus, and mammary gland (vide infra). Five
independent lines that transmitted the transgene were
established; four of these displayed an easily observable
sparse hair phenotype. None of these lines showed signif-
icant neo-natal mortality, and only line 2 produced signif-
icantly fewer transgenic than non-transgenic progeny (4.1
± 2.2 non-transgenic pups at weaning, 2.2 ± 2.0 transgenic
pups at weaning, p = 0.00075). We have been unable to
demonstrate transgene expression in the fifth line (line 6,
no observable hair phenotype) in either skin or mammary
gland, and this line was not studied further.
Mice were maintained in a light and temperature control-
led room in an AAALAC-accredited facility, and given
water and lab chow ad libitum. All experimental proce-
dures were approved by the Institutional Animal Care and
Use Committee.
Genotyping was performed using genomic DNA purified
from tail snips as template. For most of these studies, a
previously described PCR assay [19] was used. Alterna-
tively, a real time PCR assay for the coding region of
human ATF3 (Hs00231069_m1, Applied Biosystems,
Foster City, CA) was utilized, with analysis on an Applied
Biosystems 7900 HT. A positive control assay for an
endogenous murine gene (Atf3, Gapdh or Rash) was also
performed with each DNA sample.
Histopathology and Immunohistochemistry
Tissues obtained at necropsy were fixed in buffered neu-
tral formalin and paraffin embedded. Sections were pre-
pared and stained (either with hematoxylin and eosin or
for IHC) by the Tissue Processing Facility Core of the
Center for Research on Environmental Disease. Tissue
microarrays containing normal human mammary sam-
ples and breast cancer samples were the kind gift of Dr.
A.J.P. Klein-Szanto (Fox Chase Cancer Center), or were
purchased from Zymed (San Francisco, CA). For IHC,
antigen retrieval was performed as described [19]. Binding
of primary antibodies to tissue sections was visualized
with a chromogenic substrate, using a secondary antibody
coupled to horseradish peroxidase as described [19]. The
sources of the primary antibodies were as follows: CK5,
CK6, CK10, Covance (Berkeley, CA); CK8, Developmen-
tal Studies Hybridoma Bank (U. of Iowa, Ames, IA); Ki67,
Dako (Carpinteria, CA); ATF3, ERα, ErbB2, Santa Cruz
(Santa Cruz, CA). Polyclonal antibodies specific for inner
root sheath keratins mIRSA2 and mIRSA3.1 [25] were
generously provided by Dr. R.M. Porter (University of
Cardiff). The blocking peptide for ATF3 IHC (sc-188p)
was obtained from Santa Cruz (Santa Cruz, CA). IHCs for
each marker were prepared from at least 10 mammary
tumors obtained from 10 different animals. For quantita-
tive analyses of cytoplasmic expression of CK10, over
1000 cells/tumor were evaluated in three micrographs
prepared from each of the 10 tumors.
Immunoblotting
The fourth and fifth mammary glands were obtained from
virgin female mice, either non-transgenic FVB, or from
BK5.ATF3, lines 1–4. Nuclear extracts were prepared using
the NE-PER kit (Pierce). 60 μg of nuclear extract were elec-
trophoresed on 4–20% SDS-polyacrylamide gels and
transferred onto Immobilon-FL membranes (Millipore);
RAW 264.7 whole cell lysate (Santa Cruz, sc-2211) was
used as a positive control. Rabbit polyclonal anti-ATF3 or
anti β-actin antibodies (Santa Cruz) and ECL Plus (Amer-
sham) were used to detect the respective proteins.
Statistics
The incidence of squamous metaplastic lesions in nullipa-
rous females was compared between transgenic and non-
transgenic animals by Fisher's exact test. Differences in
survival between genotypes and groups were analyzed by
logrank test. Quantitative differences in litter size and
transmission of the transgene were analyzed by t-test.
Results
Mammary glands show aberrant growth in virgin 
BK5.ATF3 animals
As described elsewhere [19], transgenic BK5.ATF3 animals
exhibit several epidermal phenotypes, including sparse
hair, marked hyperplasia of the outer root sheath cells of
the hair follicle, inability to complete the hair cycle, and
mild chronic hyperplasia of the interfollicular epidermis.
Late in life, hyperplasia, dysplasia and frank neoplasia is
seen in the oral cavity, but no epidermal tumors have
been observed.
The ducts of the mammary gland are composed of two
layers of epithelial cells: an outer layer of myoepithelial
cells that express CK5 (Figure 1a, red) and an inner layer
of luminal cells that express CK8 (Figure 1a, green). Thus,
the myoepithelial cells of BK5.ATF3 mice might be
expected to express ATF3, and this was confirmed by IHC
in mammary gland sections of 8 week old BK5.ATF3 mice
(Figure 1b,d). The immunohistochemically-detected
ATF3 protein appeared to be concentrated in the nuclei of
the myoepithelial cells, as expected for a transcription fac-
tor. No ATF3 expression was detectable by IHC in the
mammary glands of wild type littermates (Figure 1c,e),
although the antibody used cross-reacts with ATF3 of both
human and murine origin [26]. This is not unexpected,
since ATF3 expression is typically only detected after treat-
ments that induce DNA damage or other conditions of
cellular stress [19-22]. Analysis of nuclear extracts by
immunoblotting revealed strong expression of the protein
in BK5.ATF3 line 1 (Figure 1f, lane 1), weaker expressionBMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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ATF3 expression in myoepithelial cells of BK5.ATF3 mice Figure 1
ATF3 expression in myoepithelial cells of BK5.ATF3 mice. (a). A paraffin section (4 μm) of a mammary gland from an 
8 week old BK5.ATF3 virgin female was stained with fluorescently labeled antibodies to CK5 (Texas Red, red) and CK8 (FITC, 
green) and examined by fluorescence microscopy. (b-e). Sections were also treated with a primary antibody to ATF3, then 
stained using horseradish peroxidase-coupled secondary antibody and a chromogenic substrate that produces a brown stain, 
and counterstained with hematoxylin. Mammary gland from a BK5.ATF3 transgenic female (b,d) was compared with a non-
transgenic littermate (c,e). Scale bars = 100 μm; scale bar in panel c applies to panels b and c, scale bar in panel e applies to pan-
els d and e. (f). Nuclear extracts were analyzed for ATF3 protein expression by immunoblotting as described in Materials and 
Methods. Equal amounts of protein from mammary glands of non-transgenic mice (lane WT) or BK5. ATF3 mice of line 1 (lane 
1), line 2 (lane 2), line 3 (lane 3), or line 4 (lane 4) were analyzed. As a positive control, an extract from RAW 264.7 cells was 
analyzed (lane C). β-actin was used as loading control. An ATF3-specific band was detected in the 20–25 KD size range in the 
BK5.ATF3 mammary gland extracts and in the positive control extract; this band was barely detectable in extracts from non-
transgenic mice (lane 1). The ATF3 band was abolished by preincubation with the ATF3 blocking peptide (not shown).BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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in lines 2–4 (lanes 2–4) and barely detectable expression
in non-transgenic animals (lane WT), presumably due to
endogenous ATF3.
When mammary glands were examined in somewhat
older virgin females (14–32 weeks), numerous dysplastic
lesions were found in all four independently derived
BK5.ATF3 transgenic lines. For many of the affected
glands, multiple ducts exhibited squamous metaplasia
(Figure 2a, arrows), and a sizeable fraction of the gland
was abnormal. The lumens of the affected ducts were
filled with keratin, and, depending on the plane of the sec-
tion, often appeared as cysts. In BK5.ATF3 line 1, squa-
mous metaplastic lesions were seen in 15 of 21 transgenic
females examined; no lesions were seen in 18 non-trans-
genic animals examined (Table 1). This difference in inci-
dence is statistically significant (Fisher's exact test, p =
2.84 × 10-6). The other three transgenic lines examined
exhibited squamous metaplastic mammary lesions in
from 46.2 to 66.7% of the animals examined (Table 1); in
all cases the difference between transgenic and non-trans-
genic animals was statistically significant (Fisher's exact
test, p < 0.001). In transgenic lines 1 and 2, over 20% of
the glands contained one or more lesions; this fraction
was somewhat lower in the other two lines (Table 1).
Expression of CK5 in these lesions was most intense in the
outermost, basal-like layer of cells, and in all lesions mul-
tiple layers of CK5-immunoreactive cells were seen
(arrow, Figure 2b). Cytokeratin CK6, not normally
observable in mammary ducts of post-pubescent animals,
was strongly expressed throughout the lesions (Figure 2c).
Expression of CK8 within the lesions was variable; when
present, the cells stained intensely (Figure 2d, arrows), but
other areas appeared to completely lack CK8 expression
(Figure 2d, arrowhead). The basal-like outer layer of cells
(denoted by an asterisk in Figure 2e &2f) routinely
expressed nuclear ATF3 (Figure 2e, arrow) and the Ki67
proliferation marker (data not shown). Strong staining for
the interfollicular epidermal keratin CK10 [27] was also
seen in some lesions (Figure 2f, arrow), and when present
was noted to be expressed supra-basally. An additional
marker of squamous differentiation, keratohyaline gran-
ules, could be seen in most lesions (Figure 2e, arrow-
head).
Mammary tumors develop in parous BK5.ATF3 mice
Initially, BK5.ATF3 females were used as breeders to main-
tain the lines by mating with non-transgenic FVB/N
males. However, litter sizes at weaning tended to be
smaller for transgenic dams (6.4 ± 2.2 pups) compared to
non-transgenic dams (8.5 ± 2.9 pups), the pups had lower
weights, and the pups (both transgenic and non-trans-
genic) were apparently unable to suckle from several teats
(data not shown). Because of these problems, it was
decided to retire the transgenic dams, and maintain the
line by mating BK5.ATF3 males to FVB/N dams. Unex-
pectedly, three of three retired BK5.ATF3 line 1 female
breeders developed large mammary tumors between 6
months and 1 year of age.
To better understand this finding, cohorts of non-trans-
genic FVB/N and BK5.ATF3 line 1 females were either
maintained as virgins for 16 months, or mated and
allowed to raise pups to weaning twice between the
ages of 6 and 13 weeks. All animals were monitored
weekly for palpable mammary masses and sacrificed
when such masses reached 1.5 cm in diameter or when
the animals became moribund. Surviving animals were
sacrificed at 16 months. The survival of BK5.ATF3 and
non-transgenic, biparous female mice is shown in Fig-
ure 3a. No suspicious masses were observed in the bipa-
rous wild-type mice (red squares), and none were seen
in virgin non-transgenic or BK5.ATF3 mice during the
16 month observation period (data not shown). Mam-
mary tumor incidence reached 67% within the bipa-
rous BK5.ATF3 group (blue triangles) by 12 months of
age. Logrank analysis of the survival curves indicated a
significant difference between the biparous BK5.ATF3
group and the biparous non-transgenic group (p =
0.0005).
At necropsy, the masses were found to be confined to the
mammary glands. About 80% of the tumor-bearing ani-
mals (12 out of 15; this includes 3 transgenic tumor-bear-
ing mice examined after the original survival study was
completed) had masses in more than one gland. All mam-
mary masses occurring in the biparous BK5.ATF3 mice
were examined by hematoxylin and eosin staining of par-
affin sections and found to be carcinomas with squamous
differentiation; examples of the histopathology are shown
in Figure 3b–h. The bulk of the tumors consisted of large,
cystic lesions with a well-defined epithelium surrounding
keratinaceous debris, dead cells and infiltrating inflam-
matory cells (Figure 3b &3c). Significant atypia and dys-
plasia could be observed in all tumors. In some areas, the
epithelial component was relatively well organized (Fig-
ure 3d), with a basal layer one-two cells in thickness, and
suprabasal components that mimicked squamous differ-
entiation, including the appearance of keratohyaline
granules adjacent to the keratinaceous core (arrows). In
other areas, the epithelial component became more
hyperplastic (Figure 3e), more anaplastic with increasing
signs of atypia (Figure 3f), and finally transitioned into
frank neoplasia, exhibiting features of squamous cell car-
cinoma (Figure 3g &3h). Atypia was noted in all layers
(Figure 3h), and atypical, enlarged nuclei were evident
(arrow). The stroma of the tumors was extremely cellular,
with abundant inflammatory infiltrates. Signs of stromal
invasion were seen in most lesions (for example,
Figure 3g).BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
Page 6 of 18
(page number not for citation purposes)
Squamous metaplasia in virgin transgenic animals Figure 2
Squamous metaplasia in virgin transgenic animals. Mammary glands from 21 nulliparous, BK5.ATF3 line 1 mice 
between 14 and 32 weeks of age and 18 age-matched, nulliparous non-transgenic littermates were examined histologically and 
by IHC. Transgenic mice from three other BK5.ATF3 lines that express the transgene were also examined (Table 1). (a) A low 
power view of multiple squamous metaplastic lesions in a single gland of a BK5.ATF3 line 4 female. (b-f) Two typical, cystic 
lesions from BK5.ATF3 line 1 mammary glands are shown, stained for (b) CK5; (c) CK6; (d) CK8; (e) ATF3; (f) CK10. Scale bar 
in a = 200 μm; scale bar in b = 100 μm, applies to panels b, c, and d; scale bar in f = 100 μm, applies to panels e and f.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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Immunohistochemistry indicated that the outermost,
basal layers of tumor cells (that is, furthest removed from
the keratinaceous core) typically exhibited nuclear expres-
sion of the ATF3 transgene (Figure 4a), and were enriched
for dividing cells as shown by expression of the Ki67 pro-
liferation marker (Figure 4b). CK5 immunoreactivity,
characteristic of basal epithelial cells, was high in both
basal and supra-basal layers of the metaplastic lesions vir-
tually throughout all tumors examined (Figure 4c). In rare
areas, CK5 expression was confined to the most basal cell
layer (not shown). Stromal components (S) were not
immunoreactive for CK5 except for scattered "nests" of
tumor cells (Figure 4c, arrowheads). Interestingly, CK8,
characteristic of luminal mammary epithelial cells, was
also expressed in both basal and supra-basal cells in 14 of
14 tumors examined (Figure 4d). Co-expression of CK5
and CK8 throughout all layers of the epithelial compo-
nent was the predominant expression pattern in 9 of these
tumors. In the remaining 5 tumors, approximately half of
the epithelial component of the tumors showed this
expression pattern. The remaining areas either exhibited
no expression of CK8, or expression was much stronger in
basal cells than in supra-basal cells. The widespread,
intense expression of CK8 confirms that the tumors arise
from mammary epithelium.
In most human breast tumors that express both CK5 and
CK8, these two cytokeratins are generally confined to dis-
tinct sub-populations of tumor cells. Thus, our finding
from the standard IHC studies that the majority of tumor
cells in the ATF3-induced murine tumors stained for both
CK5 and CK8 was somewhat unusual. To confirm this
finding, we repeated the IHC analysis using anti-CK5 anti-
body tagged with a red fluorescent dye, and anti-CK8 anti-
body tagged with a green fluorescent dye, and analyzed
the results by fluorescence microscopy. Figure 5, panels a
and b shows a representative portion of a BK5.ATF3 mam-
mary tumor photographed with filters for the individual
dye-tagged antibodies, with the two signals merged in
panel c. Groups of fluorescently-labeled tumor cells in a
background of unlabeled stroma were seen with both
antibodies, and the merged image indicates that these
groups are in many cases approximately co-extensive.
Within a group, the fluorescent intensities in individual
cells varied over a broad range for both antibodies. For
example, in the tumor cell island marked with a white
asterisk in panel b, highly fluorescent and barely fluores-
cent CK8-labeled cells were seen, and the physical extent
of the CK5 labeling in this island suggests the presence of
CK5-stained cells that do not stain for CK8 (asterisk in
panel a). Conversely, the white arrowhead in panel b
marks a cell that appeared to be CK8-positive and CK5-
negative. However, the most common pattern seen was
expression of both markers in individual cells, albeit at
different levels of intensity. This was particularly evident
in the appearance of yellow cells (white arrows) in the
merged image of panel c. The predominant pattern of co-
expression of cytokeratins characteristic of both the
myoepithelial lineage (CK5) and the luminal lineage
(CK8) suggests that the tumors may arise from progenitor
cells capable of contributing to both major lineages.
Cytokeratin CK6 is generally not found in adult ductal
mammary gland epithelium, but has been suggested to be
a marker of mammary progenitor cells [14]. Indeed mam-
mary tumors with phenotypic characteristics similar to
those described here have been suggested to arise from
mammary progenitor or stem cells [14]. Essentially all
cells in the suprabasal layers of the BK5.ATF3 mammary
tumors clearly expressed CK6 (Figure 4e, arrows). How-
ever, CK6 expression was generally absent in the basal,
rapidly dividing cell layer (Figure 4e, asterisk), which is
expected to contain the least differentiated, most "primi-
tive" cells. Scattered cells within the basal layers did
exhibit CK6 expression (Figure 4e, arrowheads). It is
worth noting that supra-basal expression of CK6 is charac-
teristically found in hair follicles [28].
Further analysis of the BK5.ATF3 mammary tumors
revealed deeper anomalies in cytokeratin expression that
are not easily explained solely by mammary stem cell ori-
gin. Because the tumors exhibit squamous differentiation,
the possibility existed that epidermal differentiation
markers would be expressed in the tumors. As basal kerat-
inocytes differentiate and move into the suprabasal layers
of the epidermis, cytokeratin expression shifts from CK5
and CK14 to CK1 and CK10, two epidermal-specific kerat-
ins [27]. Analysis of ATF3-induced mammary tumors
Table 1: Squamous metaplasia in nulliparous females
Line Non-transgenic Line 1 TG Line 2 TG Line 3 TG Line 4 TG
No. of Animals Examined 18 21 9 13 13
No. of Animals with metaplasia 0 15 9 6 6
Incidence of Metaplasia - 0.714 0.667 0.462 0.462
No. of Glands Examined 108 151 84 116 107
No. of Squamous Metaplasias 0 32 23 6 11
Fraction of Glands with
Metaplasia - 0.21 0.27 0.05 0.1BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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Mammary tumors in parous BK5.ATF3 mice Figure 3
Mammary tumors in parous BK5.ATF3 mice. (a). Female wild-type mice (n = 12, closed squares) or BK5.ATF3 mice (n 
= 15, closed triangles) were allowed to mate and raise pups twice between 6 and 24 weeks of age, then observed until 16 
months of age. Mice were euthanized when tumors reached 1.5 cm. Groups of nulliparous wild type (n = 20) and BK5.ATF3 (n 
= 13) females were also maintained for 16 months (data not shown); survival of both of these groups was 100% at the conclu-
sion of the experiment. Sections of two representative tumors arising in BK5.ATF3 mice are shown at low power (b,c; scale 
bar = 200 μm); sections from five different tumors are shown at higher power (d-h; scale bar = 50 μm). KC, keratinaceous 
core.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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ATF3, Ki67 and cytokeratin expression in BK5.ATF3 mammary tumors Immunohistochemistry of representative tumors aris- ing in BK5.ATF3 mice utilizing primary antibodies directed against ATF3 (a), Ki67 (b), CK5 (c), CK8 (d), and CK6 (e) Figure 4
ATF3, Ki67 and cytokeratin expression in BK5.ATF3 mammary tumors. Immunohistochemistry of representative 
tumors arising in BK5.ATF3 mice utilizing primary antibodies directed against ATF3 (a), Ki67 (b), CK5 (c), CK8 (d), and CK6 
(e). Scale bars = 100 μm. KC, keratinaceous core; S, stroma.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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tumors examined (Figure 6a). On average, about 46.6%
(range 38–61%, standard deviation 6.3%) of the tumor
cells expressed CK10. Generally, CK10 expression was not
seen in basal cells (indicated in Figure 6a by asterisks), but
was confined to the suprabasal layers (Figure 6a, arrow-
heads). Uninvolved mammary ducts of tumor-bearing
animals were generally negative for CK10 expression,
although scattered light background staining of stromal
elements was seen (Figure 6b). We also looked for mark-
ers of hair follicle differentiation. Type I and type II kerat-
ins that are apparently only expressed in the supra-basal
inner root sheath cells of hair follicles have been described
[25]. IHC analysis with antibodies specific for the inner
root sheath-specific type I keratin mIRSa.2 showed wide-
spread, medium intensity staining of supra-basal tumor
cells in 10 of 10 tumors examined (Figure 6c, arrow-
heads). Generally, the basal-most 2–3 cell layers (Figure
6c, asterisks) were unstained. The generalized, supra-basal
staining was somewhat more intense than background
staining seen in stromal elements of uninvolved, adjacent
mammary gland tissue with this antibody (Figure 6d,
arrow); no unequivocal staining of ductal epithelial cells
was seen in uninvolved ducts. In addition to this general-
ized, medium intensity staining, scattered single cells and
groups of cells stained intensely for mIRS.a2 in all tumors
examined (Figure 6c, arrows). A second inner root sheath-
specific type I cytokeratin, mIRS.a3.1, gave essentially the
same results in 10 of 10 tumors examined (Figure 6e). The
generalized, supra-basal staining pattern was weaker, but
strong expression in scattered groups of tumor cells was
seen in all tumors examined, comparable to the mIRS.a2
staining intensity (Figure 6e, arrows). Again, apparent
background staining in uninvolved mammary ducts was
seen in scattered stromal elements, and no unequivocal
staining of ductal epithelium was seen (Fig. 6f). Thus, not
only differentiation markers of two mammary cell line-
ages, but also differentiation markers of several epithelial
lineages of the epidermis are expressed in these tumors.
This suggests that over-expression of ATF3 results in fun-
damental alterations in the differentiation status of the
affected tumor cells, including expression of markers char-
acteristic of multiple tissues and epithelial lineages.
Several markers commonly used to classify human breast
tumors were analyzed in these tumor specimens to begin
to understand the genesis of the ATF3-induced tumors.
Expression of ERα is an important prognostic factor in
human breast cancer: tumors that are ERα+ have a more
favorable prognosis. Over 90% (13 of 14 tumors exam-
ined) of the mammary tumors that developed in parous
BK5.ATF3 female animals showed significant nuclear
expression of ERα (Figure 7a). In about 40% of the
tumors, expression was widespread, with apparent expres-
sion in both basal (arrows) and supra-basal (arrowheads)
Co-expression of CK5 and CK8 in tumor cells Figure 5
Co-expression of CK5 and CK8 in tumor cells. A paraf-
fin section of a mammary tumor arising in a BK5.ATF3 
parous female was stained with fluorescently labeled antibod-
ies to CK5 (Texas Red, red) and CK8 (FITC, green) and 
examined by fluorescence microscopy. (a), CK5 (b), CK8 (c), 
merged image.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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Deregulation of cytokeratin expression in BK5.ATF3 mammary tumors Immunohistochemistry of representative mammary  tumors arising in BK5.ATF3 mice (a,c,e) or uninvolved mammary ducts of tumor-bearing animals (b,d,f) was performed with  primary antibodies to CK10 (a,b), mIRS.a2 (c,d) and mIRS.a3.1 (e,f), and stained with the chromogenic substrate Figure 6
Deregulation of cytokeratin expression in BK5.ATF3 mammary tumors. Immunohistochemistry of representative 
mammary tumors arising in BK5.ATF3 mice (a,c,e) or uninvolved mammary ducts of tumor-bearing animals (b,d,f) was per-
formed with primary antibodies to CK10 (a,b), mIRS.a2 (c,d) and mIRS.a3.1 (e,f), and stained with the chromogenic substrate. 
Scale bar = 100 μm. KC, keratinaceous core; S, stroma.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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tumor cell nuclei. In the remaining tumors, expression
was high in most regions of the tumor, but other regions
were negative for ERα. Within ERα+ regions of ten tumors
examined in detail, an average of 74% of the cells
expressed ERα (range 54–88%). In uninvolved regions of
the mammary gland adjacent to the tumors, 50–60% of
the ductal cells were ERα+ (Figure 7b). In contrast, no
tumors examined were markedly positive for ErbB2, a
well-known mammary oncogene that is often amplified
and overexpressed in human breast tumors. No expres-
sion was seen in 4 of 10 tumors examined, and the
remaining tumors were marginally positive, with less than
10% of the tumor cells stained. As seen in Figure 7d, even
in marginally positive tumors ErbB2 staining was rela-
tively weak (compare with staining in a tumor derived
from a transgenic MMTV.neu mouse, Figure 7e). Interest-
ingly, both of these markers were expressed at moderate to
high levels in most of the metaplastic lesions seen in
mammary glands of virgin BK5.ATF3 females
(Figure 7c,f).
Expression of ATF3 in human breast tumors
Almost 70% of human breast tumors exhibit amplifica-
tion of parts of the q arm of chromosome 1 [29-32]. The
ATF3 gene is located at 1q32.1, in a region often overrep-
resented as detected by comparative genomic hybridiza-
tion studies. Direct measurements of ATF3 copy number
by quantitative PCR indicated some amplification in
~80% of human breast tumors [33]. As part of a more
extensive study of gene expression signatures in human
breast tumors, expression of ATF3 was measured in a
series of 28 early (stage 1–2) breast tumor samples.
Although ATF3 expression is barely detectable in normal
mammary cells, expression at high levels (at least 4-fold
higher than the mean of all genes assayed) was detected in
many of the samples (manuscript in preparation). Fur-
thermore, overexpression of ATF3 protein in 50% of
human breast tumors has recently been reported by Hai
and co-workers [33].
To determine whether the overexpression detected at the
RNA level and by immunoblotting was reflected in pro-
tein expression levels in the epithelial component of
human tumors, paraffin-embedded sections were
obtained from 18 early breast tumors, similar to those
studied at the RNA level, and analyzed for ATF3 protein by
IHC. Sections derived from non-tumorous mammary tis-
sue (mammoplasty specimens) were also analyzed. Adja-
cent sections were analyzed in parallel by IHC for CK5 or
after staining with hematoxylin and eosin to better define
the cellular elements of the tumors. Many of the tumors
exhibited low levels of cytoplasmic expression of ATF3, as
well as scattered positive nuclei (Figure 8a, arrows). In
addition, almost all of the tumors (17 of 18) exhibited dif-
fuse staining of stromal elements, including adipocytes,
fibroblasts and infiltrating inflammatory cells; a repre-
sentative view is shown in Figure 8a (arrowheads). When
a blocking peptide was added prior to addition of the
ATF3 primary antibody, staining of both stromal and epi-
thelial components was abolished, confirming the specif-
icity of IHC staining (Figure 8b). About 40% of these
tumors also contained significant, well-defined regions
(i.e., foci of malignant epithelial cells surrounded by stro-
mal elements and containing at least 200 tumor cell
nuclei in the section examined) that exhibited strong
nuclear staining in at least 30% of the nuclei. An example
is shown in Figure 8c. To identify the epithelial portion of
the tumor, an adjacent section was stained for CK5 (Figure
8d), and the observed boundaries of the epithelial com-
ponents are indicated by a red line in both panels. In
many cases, the regions with high levels of staining
appeared to be ductal carcinoma in situ (DCIS) (e.g., Fig-
ure 8c and 8e), located within the tumor. In all cases
examined, the tumor regions that exhibited ATF3 nuclear
staining were also positive for cytoplasmic CK5 (e.g. Fig-
ure 8d) and CK8 (data not shown). None of the tumors
examined appeared to have strong nuclear ATF3 expres-
sion in all tumor cells. In addition, clear nuclear ATF3
expression was seen in hyperplastic ducts located around
the periphery of several tumors (Figure 8f); both basal and
supra-basal cells in these abnormal ducts were immuno-
reactive for ATF3.
None of the normal mammary tissues examined exhibited
staining for ATF3 in the stromal elements, and the stain-
ing of epithelial nuclei was generally much lower than in
the ATF3-positive tumors (Figure 8g–h). In some cases,
diffuse cytoplasmic staining was seen in scattered acini. A
small fraction of large, apparently normal, ducts in both
normal mammoplasty tissues and in tumor-adjacent nor-
mal tissue exhibited strong nuclear ATF3 expression in the
basal layers (not shown).
To confirm the overexpression of ATF3 protein in human
mammary tumors, tissue microarrays were obtained and
analyzed by the same method. Overall, a total of 127
cores representing mammary tumors and 13 normal
mammary glands were analyzed. Strong nuclear expres-
sion of ATF3 in the mammary tumor cells was detected in
18% of the tumors overall; none of the normal samples in
these arrays showed nuclear ATF3 expression.
Discussion
The finding that overexpression of ATF3 in basal epithelial
cells of the mammary gland induces mammary tumori-
genesis was unexpected. At the outset of this project, there
were no reports clearly identifying ATF3 as an oncogene,
although several publications suggested a role in tumori-
genesis [34-36]. Our initial description of the BK5.ATF3
mouse model [19] reported a high incidence (~70%) ofBMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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Expression of ERα and ErbB2 in BK5.ATF3 mice Figure 7
Expression of ERα and ErbB2 in BK5.ATF3 mice. Immunohistochemistry for ERα (a,b,c) or for ErbB2 (d,e,f) was per-
formed with representative sections from mammary tumors arising in BK5.ATF3 mice (a,d), from a normal appearing mature 
mammary gland (b), from a mammary tumor that developed in an MMTV.neu transgenic animal (e), or from squamous meta-
plastic lesions (c, f) that occurred in the mammary glands of nulliparous BK5.ATF3 females. Scale bar = 100 μm.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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Expression of ATF3 in human mammary tumors Figure 8
Expression of ATF3 in human mammary tumors. Paraffin sections from human invasive ductal carcinomas that were 
less than 2 cm at presentation were examined by immunohistochemistry with an antibody directed against ATF3 (a-c,e,f). In 
(b), a blocking peptide for ATF3 (sc-188p, Santa Cruz) was added prior to the ATF3 antibody; the same region of the tumor is 
shown in (a) and (b). Panels a, c, and e represent tumors from three different patients. An adjacent section to that shown in (c) 
was analyzed for CK5 expression, and the corresponding region of the tumor is shown in (d). (f) shows a hyperplastic duct 
adjacent to an ATF3-positive tumor. (g-h), paraffin sections from normal mammoplasty tissues were examined by IHC with the 
same ATF3-specific antibody. Scale bar = 100 μm.BMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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oral carcinomas in older transgenic mice of both genders,
and was the first evidence clearly suggesting that ATF3
may act as an oncogene. In addition, the hair follicles in
these mice exhibited extreme hyperplasia in the outer root
sheath, and mild hyperplasia in the interfollicular epider-
mis, including overexpression of CK6. Recently, Hai and
co-workers [33] also suggested that ATF3 is an oncogene,
based primarily on widespread overexpression of ATF3
protein in human breast tumors, detected by immunob-
lotting. We have confirmed this finding at the mRNA level
(unpublished data), but our IHC analysis (Figure 8) indi-
cates that some of this overexpression is confined to stro-
mal cells rather than carcinoma cells.
In the tumor experiment reported in Figure 3, all of the
tumors arose by one year of age, and no tumors were seen
in a total of 32 non-transgenic and 13 nulliparous
BK5.ATF3 females observed for 16 months. This makes it
extremely unlikely that the observed tumors are related to
the background pituitary adenoma-induced mammary
lesions that arise late in life in some colonies of FVB/N
mice [37,38]. In a previous study ([19] and unpublished
results) in which sagittal sections of the head were exam-
ined (2 in each animal), we identified a single pituitary
adenoma in 43 female FVB/N examined at 16 months.
Furthermore, the results of an independent tumor study
with BK5.ATF3 mice carrying a β-galactosidase reporter
gene were very similar to the results shown in Fig. 3 (ms.
in preparation); no background mammary tumors were
seen in 10 non-transgenic animals at 16 months. Since the
transgene expression is not organ-specific, it is possible
that the effects on the mammary gland are indirect, due to
overexpression in another tissue. We have not seen trans-
gene expression in several other organs that express CK5,
notably forestomach, thymus, and pancreas. Overexpres-
sion is seen in epidermis and oral epithelia [19]. Hyper-
plasia is the major phenotype seen in skin, with no
development of neoplasia. Carcinomas do develop in the
oral cavity, but the onset of tumorigenesis is delayed rela-
tive to the appearance of mammary tumors. This delay,
along with the absolute dependence of mammary tumor-
igenesis on parity, make it unlikely that an indirect effect
due to skin or oral expression of ATF3 plays a major role
in mammary tumorigenesis. We therefore conclude that
overexpression of ATF3 in the mammary gland is a con-
tributing factor for mammary tumorigenesis in this trans-
genic model.
Indeed, the biological roles played by ATF3 remain poorly
understood. ATF3 expression is a ubiquitous feature of the
response to DNA damage and other cellular stressors
[21,22,39,40], and several downstream targets have been
identified [33,41-48] without, however, providing much
insight into the physiological function of the gene. The
ATF3 response to DNA damage appears to be regulated by
p53 [39,49] and by stimulation of the MAPK pathway
[39,50], but it is a self-limiting response in that the ATF3
protein acts as an inhibitor of its own promoter [47].
There is also evidence for down-regulation of p53 by
ATF3, blocking apoptosis of cardiac myocytes treated with
doxorubicin [51] and human umbilical cord endothelial
cells treated with tumor necrosis factor-alpha [52]. Addi-
tionally, ATF3 appears to be growth stimulatory in hepa-
tocytes, dorsal root ganglion neurons, and classical
Hodgkin lymphoma cells [53-55]. In contrast to these
pro-growth/survival effects, ATF3 has also been positively
associated with growth arrest or apoptosis in human
umbilical cord endothelial cells, pancreatic beta-cells,
chondrocytes and mouse embryonic fibroblasts [35,56-
59]. Involvement of ATF3 in the normal function of the
unstressed mammary gland has not been reported.
Some insight into possible effects of ATF3 overexpression
has been provided by studies of its interactions with other
transcription factors. As a member of the bZip family of
transcription factors, ATF3 can form heterodimers with
other family members through the leucine zipper
domain, as well as forming homodimers. Known binding
partners include cJun, JunB, CEBP-γ and Ddit3 [60]. It has
been reported that ATF3 homodimers act as repressors of
transcription [23,46], while heterodimers with cJun and
JunD can activate transcription [42,61,62]. In addition,
recent studies have identified physical and functional
interactions of ATF3 with two other transcription factors,
p53 [48,63] and Smad3 [43], that are leucine zipper-
domain independent. However, physiological roles for
these heterodimers or for ATF3 homodimers in mammary
gland are unknown.
Our working hypothesis is that overexpression of ATF3 in
a CK5-expressing stem or progenitor cell (postulated to be
capable of differentiating along either myoepithelial or
luminal pathways [10,15,16]) interferes with important
cellular signaling pathways, either by a direct transcrip-
tional effect on a normal ATF3-target gene or by sequester-
ing other transcription factors. As noted above, these may
include p53, Smad3, cJun, Ddit3 and other known bind-
ing partners of ATF3. The transcriptional repression ability
of ATF3 may then effectively abrogate the function of one
or more of these pathways, and thereby initiate the proc-
ess of tumorigenesis. The absolute dependence of ATF3-
induced tumorigenesis on parity (see Figure 3) suggests
that the growth-promoting stimuli that the mammary
gland responds to during pregnancy and lactation may
promote the growth of initiated stem or progenitor cells in
the transgenic glands, eventually leading to malignant car-
cinoma.
The squamous differentiation characteristic of ATF3-
induced tumors is phenotypically exceedingly similar toBMC Cancer 2008, 8:268 http://www.biomedcentral.com/1471-2407/8/268
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tumors produced in several transgenic models in which
the Wnt/β-catenin pathway is stimulated. These models
include transgenes expressed in the basal cell compart-
ment [17] and transgenes expressed primarily in the lumi-
nal cell compartment due to the use of the MMTV
promoter [14,64-68]. In particular, the characteristics of
the BK5.ATF3 model, including the squamous differentia-
tion phenotype of the tumors, the expression of CK10,
and the dependence of tumorigenesis on parity, are very
similar to the CK5.ΔN59cat model described by Glukhova
et al. [17]. Two models explaining the squamous meta-
plastic phenotypes of the Wnt/β-catenin tumors have
been proposed. Based on expression of markers of more
"primitive" stem or progenitor cells (CK6 and Sca-1), Var-
mus and colleagues [14] suggested that the target cell pop-
ulation must be a very primitive stem cell. Alternatively, it
has been suggested [65,66] that the phenotype was due to
"transdifferentiation" to the epidermal lineage. The carci-
nomas that develop in multiparous BK5.ATF3 mammary
glands express a wide range of marker proteins, character-
istic not only of both basal and suprabasal compartments
of the mammary gland (CK5 and CK8, respectively), but
also the suprabasal compartments of the interfollicular
epidermis (K10) and the hair follicles (mIRSa.2,
mIRSa.3.1). Expression of both basal and suprabasal
markers suggests strongly that the target population for
tumorigenesis contains CK5-expressing, multi-potential
progenitor cells capable of giving rise to both basal and
suprabasal components. A model that combines compo-
nents of both the Varmus and Hennigshausen models
would be that one of the effects of ATF3 overexpression in
these progenitor cells would be to "erase" the develop-
mental specifications that mark this population as mam-
mary, and allow them to differentiate as either mammary
or epidermal, the decision presumably being stochastic.
The observed pattern of expression of the hair follicle
cytokeratins (Figure 6) is consistent with such a model, in
that the aberrant markers (mIRSa.2, mIRSa.3.1) are gener-
ally expressed in localized foci of cells, as would be
expected for a clone of tumor cells descended from a sin-
gle progenitor cell that became specified for a particular
epithelial compartment stochastically.
The finding of high levels of nuclear expression of ATF3 in
a subset of human breast tumors (Figure 8) raises the pos-
sibility that this transgenic model may provide clues as to
the genesis of at least some human cancers. Interpretation
of these results is complicated by the simultaneous expres-
sion of ATF3 at high levels in stromal components of these
tumors (Figure 8), and by the fact that expression within
the epithelial cell compartment is by no means universal
within a given tumor. Thus, it is also possible that in both
stromal and epithelial tumor components, ATF3 expres-
sion is part of an ongoing response to stressful conditions
existing within the tumor microenvironment. However,
ATF3 expression is seen more frequently in DCIS compo-
nents of the tumors, and in hyperplastic ducts adjacent to
ATF3-positive tumors. Thus, it is conceivable that aberrant
nuclear ATF3 expression is involved in the early, rather
than the late, stages of malignant transformation.
Conclusion
Overexpression of ATF3 in CK5-expressing murine mam-
mary epithelial cells results in the development of squa-
mous metaplastic mammary lesions in nulliparous mice,
and in mammary tumorigenesis in biparous mice, sug-
gesting that ATF3 acts as a mammary oncogene. The
resulting tumors aberrantly express cytokeratins that are
characteristic of several mammary and epidermal lineages
and are phenotypically similar to tumors produced in
other transgenic models that upregulate Wnt/β-catenin
signaling in the mammary gland. A subset of human
breast tumors expresses high levels of ATF3, suggesting
that ATF3 may play an oncogenic role in human breast
tumorigenesis. A better understanding of the molecular
mechanisms by which ATF3 overexpression initiates
mammary tumorigenesis in the transgenic mouse model
may provide new biomarkers and/or therapeutic targets
for a subset of human breast tumors.
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